Large scale and stable production of human FVIII in the human cell line Sk-Hep-1
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 3, 2015
Issued Date -
N/A
app pub date -
Jan 19, 2012
filing date -
Jan 24, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention refers to: 1) the method for the production of recombinant FVIII in human Sk-Hep-1 cells, comprising von Willebrand Factor (vWF) and 2) the population of human cells transduced with a vector encoding the clotting protein (FVIII). The technical object of the present patent application is intended for the cultivation of human cells in suspension and in adhesion and isolation of the culture medium containing the desired protein. The object of the invention is to provide a safer product (free of potential human viruses), that is cheaper and more stable, by means of a method that provides sufficient amounts and on industrial scale to meet the National demand.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully